Treated and Untreated Mice RNAseq Readcount files

Epilepsy is a common neurological disease; however, few if any of the currently marketed antiseizure medications prevent or cure epilepsy. Angiotensin receptor blockers (ARBs) represent a promising strategy to treat the numerous detrimental consequences of epileptogenesis.Scn8a pathology mimics the known effects of angiotensin type 1 receptor (AT1R) overstimulation and thus, blocking AT1R activation has potential therapeutic value in this model and other neurological disorders with similar pathological features.Results of testing candesartan, an FDA-approved ARB used to treat hypertension in pediatric patients older than 1 year, on this transgenic Scn8a mouse model yield strong evidence for its efficacy and support its use in clinical trials for children with SCN8A-related epilepsyFor inquiries regarding the contents of this dataset, please contact the Corresponding Author listed in the README.txt file. Administrative inquiries (e.g., removal requests, trouble downloading, etc.) can be directed to [e-mail]

癫痫病是一种常见的神经系统疾病；然而，目前市场上销售的绝大多数抗癫痫药物均无法预防或治愈癫痫。血管紧张素受体拮抗剂（ARBs）代表了治疗癫痫发生过程中众多有害后果的一种有希望的策略。Scn8a病理学模拟了已知血管紧张素1型受体（AT1R）过度刺激的效果，因此，阻断AT1R的激活在此模型及其他具有相似病理特征的神经系统疾病中具有潜在的治疗价值。对坎地沙坦（一种经美国食品药品监督管理局批准的ARB，用于治疗1岁以上儿童的高血压）在此转基因Scn8a小鼠模型中的测试结果提供了强有力的证据，证实其疗效，并支持其在儿童SCN8A相关癫痫的临床试验中的应用。有关该数据集内容的查询，请联系README.txt文件中列出的通讯作者。行政查询（例如，删除请求、下载问题等）可发送至[e-mail]。